Beyond BRCA: AstraZeneca rounds out ESMO with a case for expanded biomarker in prostate cancer
BARCELONA — When it comes to selecting patients for PARP inhibitors, mutations in the BRCA1 and BRCA2 genes have been the go-to biomarker, the surest way of finding those most likely to benefit from the therapy. But AstraZeneca and Merck are making some headway in carving out a new niche for itself in prostate cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,400+ biopharma pros reading Endpoints daily — and it's free.